@prefix dct: .
@prefix this: .
@prefix sub: .
@prefix beldoc: .
@prefix rdfs: .
@prefix rdf: .
@prefix xsd: .
@prefix dce: .
@prefix pav: .
@prefix np: .
@prefix belv: .
@prefix prov: .
@prefix chebi: .
@prefix Protein: .
@prefix rgd: .
@prefix geneProductOf: .
@prefix species: .
@prefix occursIn: .
@prefix pubmed: .
@prefix orcid: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
sub:_1 geneProductOf: rgd:2348;
a Protein: .
sub:_2 occursIn: species:10116;
rdf:object sub:_1;
rdf:predicate belv:increases;
rdf:subject chebi:18723;
a rdf:Statement .
sub:assertion rdfs:label "a(CHEBI:nicotine) -> p(RGD:Chrna7)" .
}
sub:provenance {
beldoc: dce:description "Approximately 61,000 statements.";
dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
dce:title "BEL Framework Large Corpus Document";
pav:authoredBy sub:_4;
pav:version "1.4" .
sub:_3 prov:value "Wild-type rat hippocampal slices maintained in culture exhibit activation of ERK2 MAPK with nictotine (500 microM) treatment that was blocked by methyllycaconitine (MLA, 1 microM), alpha7-selective antagonist pretreatment. These results demonstrated that alpha7 nAChR activation was capable of stimulating ERK2 MAPK in hippocampus.";
prov:wasQuotedFrom pubmed:11404397 .
sub:_4 rdfs:label "Selventa" .
sub:assertion prov:hadPrimarySource pubmed:11404397;
prov:wasDerivedFrom beldoc:, sub:_3 .
}
sub:pubinfo {
this: dct:created "2014-07-03T14:29:56.573+02:00"^^xsd:dateTime;
pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}